FHA
CRSP icon

Flagship Harbor Advisors’s CRISPR Therapeutics CRSP Stock Holding History

Flagship Harbor Advisors’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-2,961
Closed -$155K – 1014
2025
Q4 		$155K Buy
+2,961
New +$177K 0.01% 743
2024
Q4 		– Sell
-6,073
Closed -$285K – 746
2024
Q3 		$285K Sell
6,073
-195
-3% -$9.89K 0.02% 575
2024
Q2 		$339K Sell
6,268
-285
-4% -$16.5K 0.02% 506
2024
Q1 		$447K Sell
6,553
-43
-0.7% -$3.08K 0.03% 411
2023
Q4 		$413K Buy
6,596
+574
+10% +$31.7K 0.03% 405
2023
Q3 		$273K Buy
6,022
+209
+4% +$10.8K 0.02% 492
2023
Q2 		$326K Buy
5,813
+547
+10% +$31K 0.03% 450
2023
Q1 		$238K Buy
5,266
+200
+4% +$9.71K 0.02% 544
2022
Q4 		$206K Buy
5,066
+50
+1% +$2.65K 0.02% 566
2022
Q3 		$328K Sell
5,016
-36
-0.7% -$2.61K 0.04% 416
2022
Q2 		$307K Sell
5,052
-72
-1% -$4.23K 0.03% 453
2022
Q1 		$322K Buy
5,124
+233
+5% +$14.6K 0.03% 460
2021
Q4 		$371K Buy
4,891
+283
+6% +$24.7K 0.04% 442
2021
Q3 		$746K Hold
4,608
– – 0.08% 266
2021
Q2 		$746K Buy
4,608
+1,497
+48% +$182K 0.08% 267
2021
Q1 		$379K Buy
3,111
+46
+2% +$6.95K 0.04% 412
2020
Q4 		$469K Buy
3,065
+55
+2% +$6.5K 0.06% 327
2020
Q3 		$251K Sell
3,010
-690
-19% -$61.2K 0.03% 410
2020
Q2 		$271K Buy
3,700
+150
+4% +$8.77K 0.04% 382
2020
Q1 		$151K Buy
3,550
+883
+33% +$45.6K 0.03% 447
2019
Q4 		$162K Sell
2,667
-42
-2% -$2.29K 0.03% 485
2019
Q3 		$111K Sell
2,709
-600
-18% -$28.7K 0.02% 555
2019
Q2 		$155K Hold
3,309
– – 0.03% 458
2019
Q1 		$118K Buy
3,309
+600
+22% +$20.7K 0.02% 519
2018
Q4 		$77K Buy
2,709
+2,443
+918% +$84.9K 0.02% 592
2018
Q3 		$11K Sell
266
-100
-27% -$5.24K ﹤0.01% 1367
2018
Q2 		$21K Buy
+366
New +$20.9K ﹤0.01% 1072

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
GP
GSK plc London $602M AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Flagship Harbor Advisors's CRSP Position: Q1 2026 in Review

Flagship Harbor Advisors sold out of CRISPR Therapeutics (CRSP) in Q1 2026, closing a stake of 2,961 shares — an estimated $155K sold.

Flagship Harbor Advisors first reported a position in CRSP in Q2 2018 and held it in 27 quarters. The position peaked at $746K in Q3 2021. 492 funds tracked by Wall St. Rank hold CRSP as of Q1 2026.

  • Flagship Harbor Advisors reported no remaining CRISPR Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Flagship Harbor Advisors sold 2,961 CRISPR Therapeutics shares in Q1 2026, an estimated $155K.
  • Flagship Harbor Advisors first reported a position in CRISPR Therapeutics in Q2 2018 and held it in 27 quarters.
  • Flagship Harbor Advisors's CRISPR Therapeutics position peaked at $746K in Q3 2021.
  • 492 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2026.

Based on Flagship Harbor Advisors's 13F filing for Q1 2026, filed 28 Apr 2026.